{"id":"NCT00657150","sponsor":"Boehringer Ingelheim","briefTitle":"Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty","officialTitle":"A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Orally Administered 220 mg Dabigatran Etexilate Capsules (110 mg Administered on the Day of Surgery Followed by 220 mg Once Daily) Compared to Subcutaneous 40 mg Enoxaparin Once Daily for 28-35 Days, in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip Arthroplasty Surgery. (RE-NOVATE II)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2009-09","completion":null,"firstPosted":"2008-04-14","resultsPosted":"2010-12-17","lastUpdate":"2014-07-02"},"enrollment":2055,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Venous Thromboembolism"],"interventions":[{"type":"DRUG","name":"Enoxaparin","otherNames":[]},{"type":"DRUG","name":"Dabigatran etexilate","otherNames":[]}],"arms":[{"label":"Dabigatran etexilate","type":"EXPERIMENTAL"},{"label":"Enoxaparin","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of the trial is to demonstrate non-inferiority of 220 mg oral dabigatran etexilate compared to 40 mg subcutaneous enoxaparin administered once daily. Safety and efficacy will be compared between the treatment groups.","primaryOutcome":{"measure":"Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period","timeFrame":"28-35 days","effectByArm":[{"arm":"Dabigatran 220mg","deltaMin":61,"sd":null},{"arm":"Enoxaparin","deltaMin":69,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":25},"locations":{"siteCount":108,"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","Denmark","Finland","Germany","Hungary","India","Italy","Netherlands","New Zealand","Norway","Poland","South Africa","Spain","Sweden"]},"refs":{"pmids":["26578849","21225098"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":57,"n":1010},"commonTop":["Nausea","Vomiting","Constipation","Pyrexia","Haemoglobin decreased"]}}